Project Grant HT94252410378

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $427,000.00 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the New York Blood Center, Inc. to establish an in vitro culture system for the propagation of the Babesia microti parasite in human red blood cells. The overall goal is to develop a robust platform to enable future experimental investigations into the receptor-ligand interactions facilitating B. microti invasion of human red blood...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $250,573 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Pittsburgh to investigate how host genetic differences impact the transmission and pathogenesis of the tick-borne parasite Babesia microti, which causes human babesiosis. The two-year project aims to: 1) Test the hypothesis that host genetic polymorphisms significantly influence tick-transmitted B. microti infection,...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $431,143 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Tufts University School of Medicine to develop methods for the continuous in vitro culture of the parasite Babesia microti. This parasite causes the re-emerging infectious disease babesiosis, which has increased in prevalence in the Northeastern United States. The key objectives are to: 1) propagate B. microti within tick...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $134,730.00 to the New York Blood Center, Inc. to conduct research on the structural and functional alterations of host red blood cells (RBCs) by the Babesia parasite. The overarching goal is to elucidate the mechanisms underlying changes to host RBCs during Babesia infection, with the aims of mapping...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $874,372 to Yale University to conduct research on parasite-derived vesicles in Babesia virulence and vaccine development. The research aims to elucidate the molecular mechanisms by which Babesia species communicate with their host and leverage this knowledge to engineer an effective and safe vaccine for...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $520,809 in funding to Rosalind Franklin University of Medicine & Science over the period from September 5, 2024 to August 31, 2029. The overarching goal of this research project is to investigate the role of TAM receptors in modulating the humoral immune response against parasitic infections, such as malaria....

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $778,829 over 5 years to Emory University to conduct research on early life B-cell and plasma cell development in the human spleen. The key objectives are to: 1) characterize B-cell development and cytokine/metabolic regulators in early life versus adulthood; 2) examine the phenotype and functions of mature B-cell...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) provides $178,932 to the University of Maryland, Baltimore to analyze cord blood Vγ9Vδ2 (Vδ2) T cell differentiation and function using cutting-edge single-cell approaches. The award aims to investigate the significance of the inhibitory receptor PD1 in regulating Vδ2 T cell development and antimicrobial activity in early life. Utilizing Cellular Indexing...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $558,045 to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to study the role of protein phosphatase 2A (PP2A) in regulating immune cell function and metabolism in systemic lupus erythematosus (SLE). The research aims to determine how PP2A controls enzymes involved in glycolysis and the pentose phosphate pathway,...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $799,017 to Emory University to conduct research on generating highly differentiated natural killer (NK) cells that can synergize with broadly neutralizing antibodies to control viral replication in the absence of antiretroviral therapy (ART). The research aims to: 1) define the function and distribution of NK cells in...